[go: up one dir, main page]

MA29485B1 - Motilides - Google Patents

Motilides

Info

Publication number
MA29485B1
MA29485B1 MA30419A MA30419A MA29485B1 MA 29485 B1 MA29485 B1 MA 29485B1 MA 30419 A MA30419 A MA 30419A MA 30419 A MA30419 A MA 30419A MA 29485 B1 MA29485 B1 MA 29485B1
Authority
MA
Morocco
Prior art keywords
motilides
procintic
agents
employed
formula
Prior art date
Application number
MA30419A
Other languages
English (en)
Inventor
Yaoquan Liu
Christopher Carreras
David C Myles
Yong Li
Simon James Shaw
Hong Fu
Yue Chen
Hao Zheng
Yandong Li
Mark A Burlingame
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA29485B1 publication Critical patent/MA29485B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSÉS DE STRUCTURE RÉPONDANT À LA FORMULE (I) OÙ RA, RB, RC, RD, RE, ET RF SONT TELS QUE DÉFINIS DANS LA PRÉSENTE POUVANT ÊTRE EMPLOYÉS EN TANT QU'AGENTS PROCINÉTIQUES.
MA30419A 2005-05-24 2007-11-23 Motilides MA29485B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68461205P 2005-05-24 2005-05-24
US71540605P 2005-09-08 2005-09-08
US74889805P 2005-12-08 2005-12-08
US11/416,519 US7582611B2 (en) 2005-05-24 2006-05-02 Motilide compounds

Publications (1)

Publication Number Publication Date
MA29485B1 true MA29485B1 (fr) 2008-05-02

Family

ID=37452327

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30419A MA29485B1 (fr) 2005-05-24 2007-11-23 Motilides

Country Status (20)

Country Link
US (1) US7582611B2 (fr)
EP (1) EP1888082B1 (fr)
JP (1) JP4197359B2 (fr)
KR (1) KR100956465B1 (fr)
AP (1) AP2337A (fr)
AU (1) AU2006249555B2 (fr)
BR (1) BRPI0611374A2 (fr)
CA (1) CA2609494C (fr)
CU (1) CU23750B7 (fr)
EA (1) EA014711B1 (fr)
ES (1) ES2392860T3 (fr)
GE (1) GEP20094854B (fr)
HK (1) HK1117739A1 (fr)
IL (1) IL186752A (fr)
MA (1) MA29485B1 (fr)
MX (1) MX2007014255A (fr)
NO (1) NO20076464L (fr)
NZ (1) NZ562891A (fr)
TN (1) TNSN07436A1 (fr)
WO (1) WO2006127252A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632779A1 (fr) * 2005-12-08 2007-06-14 Pfizer Inc. Procede de demethylation du groupe 3'-dimethylamino de composants d'erythromycine
CA2662897C (fr) 2006-09-11 2017-11-07 Tranzyme Pharma, Inc. Antagonistes macrocycliques du recepteur de la motiline pour le traitement de troubles de dysmotilite gastro-intestinale
CA2670482C (fr) * 2006-12-05 2011-10-11 Pfizer Inc. Polymorphes du type motilide
US20080287371A1 (en) * 2007-05-17 2008-11-20 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
ES2547415T3 (es) 2009-02-27 2015-10-06 Raqualia Pharma Inc Derivados de oxiindol con actividad agonista del receptor de motilina
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983103A (en) 1973-01-19 1976-09-28 Pliva Pharmaceutical And Chemical Works N-(Benzenesulfonyl)-erythromycylamine derivatives
YU35369B (en) 1973-01-19 1980-12-31 Pliva Zagreb Process for preparing n-(benzenesulfonyl)-erythromycilamine derivatives
US3855200A (en) 1973-04-23 1974-12-17 Polska Akademia Nauk Instytut Process for preparing 8-hydroxyerthromycin a and intermediates therefor
YU35363B (en) 1974-01-14 1980-12-31 Pliva Zagreb Process for obtaining n-(benzene-sulfonyl)-5-0desosaminyl-erythromycilamine derivatives
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
IT1196041B (it) 1984-03-08 1988-11-10 Pierrel Spa Emichetali di (8s)-8-fluoroeritromicine,il procedimento per la loro preparazione e le formulazioni adatte alla somministrazione orale che contengono i prodotti
JPS60218321A (ja) 1984-04-13 1985-11-01 Satoshi Omura 消化管収縮運動促進剤
US5175150A (en) 1985-08-31 1992-12-29 Kitasato, Kenkyusho Erythromycin derivative
US5008249A (en) 1985-08-31 1991-04-16 Kitasato Kenkyusho Therapeutic method of stimulating digestive tract contractile motion in mammals
IL99995A (en) 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
KR100222014B1 (ko) 1991-04-09 1999-10-01 스티븐 에프. 웨인스톡 거대환식 락탐 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US5523401A (en) 1991-04-09 1996-06-04 Abbott Laboratories Macrocyclic lactam prokinetic agents
DE4200145A1 (de) * 1992-01-07 1993-07-08 Kali Chemie Pharma Gmbh 7,10-epoxy-oxacyclododecan-derivate, verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
MX9300278A (es) 1992-01-21 1993-12-31 Abbott Lab Compuestos de arilalcoxifenoxi-imidazolina.
CA2092045C (fr) 1992-03-19 2004-08-10 Setsuo Harada Derives de l'erythromycine, leur preparation et leur usage
MY113693A (en) 1992-05-26 2002-05-31 Chugai Pharmaceutical Co Ltd Erythromycin derivatives having an enterokinesis stimulating action
ZA966601B (en) 1995-08-03 1997-02-19 Chugai Pharmaceutical Co Ltd Process for producing erythromycin derivatives.
EP0918783A1 (fr) 1996-05-07 1999-06-02 Abbott Laboratories Erythromycines 6-o substituees et leur procede de preparation
US5712253A (en) 1996-06-18 1998-01-27 Abbott Laboratories Macrocyclic 13-membered ring derivatives of erythromycins A and B
EP0909327B1 (fr) * 1996-07-05 2005-06-01 Biotica Technology Limited Erythromycines et leur procede de preparation
HRP960497B1 (en) * 1996-10-28 2003-08-31 Pliva Pharm & Chem Works 9-n-ethenyl derivatives of 9(s)-erythromycylamine
US5922849A (en) 1996-11-22 1999-07-13 Abbott Laboratories Process for preparation of N-demethyl-4"-deoxy-erthromycins A and B
AU9646098A (en) 1997-10-29 1999-05-17 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
US6084079A (en) 1998-05-15 2000-07-04 Keyes; Robert F. Process for preparing N-demethyl-N-alkyl erythromycin derivatives
KR100317907B1 (ko) * 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
IT1306205B1 (it) * 1999-01-15 2001-05-30 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
JP2003523347A (ja) 2000-02-18 2003-08-05 コーサン バイオサイエンシーズ， インコーポレイテッド モチライド化合物
AU8257701A (en) * 2000-09-01 2002-03-13 Chugai Pharmaceutical Co Ltd Process for producing erythromycin derivative
US20020094962A1 (en) 2000-12-01 2002-07-18 Gary Ashley Motilide compounds
CA2437576A1 (fr) 2001-02-15 2002-08-22 Kosan Biosciences, Inc. Procede pour evaluer l'efficacite therapeutique
JP2002241391A (ja) 2001-02-15 2002-08-28 Taisho Pharmaceut Co Ltd エリスロマイシンａ誘導体
CN100363359C (zh) 2002-08-29 2008-01-23 菲塞股份有限公司 运动内酯化合物
US7407941B2 (en) 2003-08-26 2008-08-05 Pfizer, Inc. N-desmethyl-N-substituted-11-deoxyerythromycin compounds
US20050113319A1 (en) 2003-08-26 2005-05-26 Christopher Carreras 11-Deoxy-6,9-ether erythromycin compounds
EP1682563A1 (fr) 2003-10-30 2006-07-26 Rib-X Pharmaceuticals, Inc. Composes heterocycliques macrolidiques bifonctionnels et leurs procedes de preparation et d'utilisation
US7211568B2 (en) 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
US20060075011A1 (en) * 2004-09-23 2006-04-06 Fujitsu Limited System and method for optimizing polynomial expressions in a processing environment
TW200633714A (en) 2004-12-28 2006-10-01 Chugai Pharmaceutical Co Ltd Drugs for the treatment and/or prophylaxis of gastroparesis symptom

Also Published As

Publication number Publication date
CU23750B7 (es) 2012-01-31
WO2006127252A1 (fr) 2006-11-30
HK1117739A1 (en) 2009-01-23
KR100956465B1 (ko) 2010-05-07
EP1888082B1 (fr) 2012-09-12
GEP20094854B (en) 2009-12-10
TNSN07436A1 (fr) 2009-03-17
AU2006249555B2 (en) 2009-07-16
JP2008542268A (ja) 2008-11-27
AU2006249555A1 (en) 2006-11-30
EP1888082A4 (fr) 2008-12-17
EA014711B1 (ru) 2011-02-28
AP2337A (en) 2011-12-14
NO20076464L (no) 2008-02-22
KR20080013922A (ko) 2008-02-13
AP2007004220A0 (en) 2007-10-31
IL186752A (en) 2011-10-31
US20060270616A1 (en) 2006-11-30
ES2392860T3 (es) 2012-12-14
EA200702290A1 (ru) 2008-04-28
CA2609494A1 (fr) 2006-11-30
AU2006249555A8 (en) 2006-11-30
NZ562891A (en) 2011-01-28
CA2609494C (fr) 2010-12-21
IL186752A0 (en) 2008-02-09
JP4197359B2 (ja) 2008-12-17
BRPI0611374A2 (pt) 2010-08-31
MX2007014255A (es) 2008-01-22
US7582611B2 (en) 2009-09-01
EP1888082A1 (fr) 2008-02-20
CU20070261A7 (es) 2009-07-16

Similar Documents

Publication Publication Date Title
MA29485B1 (fr) Motilides
MA32893B1 (fr) Pesticedes composes de n-oxypiperidines spiroheterocycliques
MA38826B1 (fr) Nouveaux dérivés de triazolo[4,5-d]pyrimidine
MA31597B1 (fr) Nouveaux herbicides
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
EP2033688A3 (fr) Dérivés d'acide oxalique et leur utilisation en tant que matières de refroidissement physiologiques
RS52632B (en) S-TRIAZOLYL ALFA-MERCAPTOACETANILIDE AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
EA200801794A1 (ru) Гербицидная композиция в виде стабильного концентрата
MA40308A1 (fr) Pyridine-2- amides utiles comme agonistes de cb2
RS52214B (en) HDAC INHIBITOR PHARMACEUTICAL FORMULATIONS
BRPI0606379A2 (pt) triazolftalazinas
MA33420B1 (fr) Dérivés fluorés de l'aminotriazole
MA31467B1 (fr) Composes 1, 3-dione bicycliques actifs sur le plan herbicide.
RS51970B (en) TRICYCLIC UNITS AND THEIR USE AS MODULATORS OF GLUCOCORTICOID RECEPTORS
DE602008005643D1 (de) Parathormon-formulierungen und ihre anwendungen
HRP20080529T3 (en) Amide prodrug of gemcitabine, compositions and use thereof
EA200801351A1 (ru) Фунгицидные смеси, которые содержат боскалид и пириметанил
BRPI0606081A (pt) método e sistema para impor restrições sobre sessões
DE602006019832D1 (de) Isoflavonoiddimere
CR10303A (es) "derivados de quinolina y su uso com pesticidas"
BR0314058A (pt) Composições para cuidados pessoais a base de álcool ramificado
CL2004000804A1 (es) Procedimiento de preparacion en una sola etapa de n-(n'-glicilo substituida)-2-cianopirrolidina.
ATE464307T1 (de) Mif-hemmer
CO6251376A2 (es) Triazolilpiridina cetonas herbicidas
NL1033024A1 (nl) Interferometer met geringe afwijking ('walk-off').